Find Research Outputs

Search concepts
Selected filters

Publication Year

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

Author

  • Isamu Okamoto
2020

Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors

Takada, K., Yoneshima, Y., Tanaka, K., Okamoto, I., Shimokawa, M., Wakasu, S., Takamori, S., Toyokawa, G., Oba, T., Osoegawa, A., Tagawa, T., Oda, Y., Nakanishi, Y. & Mori, M., Jan 1 2020, (Accepted/In press) In : Journal of Cancer Research and Clinical Oncology.

Research output: Contribution to journalArticle

Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study

Senan, S., Okamoto, I., Lee, G. W., Chen, Y., Niho, S., Mak, G., Yao, W., Shire, N., Jiang, H. & Cho, B. C., Mar 2020, In : Clinical Lung Cancer. 21, 2, p. e84-e88

Research output: Contribution to journalArticle

Open Access

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy

Tokudome, N., Koh, Y., Akamatsu, H., Fujimoto, D., Okamoto, I., Nakagawa, K., Hida, T., Imamura, F., Morita, S. & Yamamoto, N., Feb 6 2020, In : BMC Cancer. 20, 1, 103.

Research output: Contribution to journalArticle

Open Access

Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors

Iwama, E., Sakai, K., Hidaka, N., Inoue, K., Fujii, A., Nakagaki, N., Ota, K., Toyozawa, R., Azuma, K., Nakatomi, K., Harada, T., Hisasue, J., Sakata, S., Shimose, T., Kishimoto, J., Nakanishi, Y., Nishio, K. & Okamoto, I., Jan 1 2020, In : Cancer. 126, 1, p. 219-227 9 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation

Tsutsumi, H., Yoneshima, Y., Ota, K., Otsubo, K., Iwama, E., Inoue, H., Tanaka, K., Nakanishi, Y. & Okamoto, I., Jan 2020, In : Clinical Lung Cancer. 21, 1, p. e21-e24

Research output: Contribution to journalArticle

Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study

Takahama, T., Azuma, K., Shimokawa, M., Takeda, M., Ishii, H., Kato, T., Saito, H., Daga, H., Tsuboguchi, Y., Okamoto, I., Otsubo, K., Akamatsu, H., Teraoka, S., Takahashi, T., Ono, A., Ohira, T., Yokoyama, T., Sakai, K., Yamamoto, N., Nishio, K. & 1 others, Nakagawa, K., Jan 1 2020, (Accepted/In press) In : Cancer.

Research output: Contribution to journalArticle

Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan

Morita, R., Okishio, K., Shimizu, J., Saito, H., Sakai, H., Kim, Y. H., Hataji, O., Yomota, M., Nishio, M., Aoe, K., Kanai, O., Kumagai, T., Kibata, K., Tsukamoto, H., Oizumi, S., Fujimoto, D., Tanaka, H., Mizuno, K., Masuda, T., Kozuki, T. & 6 others, Haku, T., Suzuki, H., Okamoto, I., Hoshiyama, H., Ueda, J. & Ohe, Y., Feb 2020, In : Lung Cancer. 140, p. 8-18 11 p.

Research output: Contribution to journalArticle

Open Access

Therapies after first-line afatinib in patients with EGFR m+ NSCLC in Japan: Retrospective analysis of LUX-Lung 3

Yoshioka, H., Kato, T., Okamoto, I., Tanaka, H., Hida, T., Seto, T., Kiura, K., Tian, Y., Azuma, H. & Yamamoto, N., Jan 1 2020, In : Future Oncology. 16, 4, p. 49-60 12 p.

Research output: Contribution to journalArticle

Open Access
2019

18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer

Takada, K., Toyokawa, G., Yoneshima, Y., Tanaka, K., Okamoto, I., Shimokawa, M., Wakasu, S., Haro, A., Osoegawa, A., Tagawa, T., Oda, Y., Nakanishi, Y. & Mori, M., Dec 1 2019, In : Scientific reports. 9, 1, 13362.

Research output: Contribution to journalArticle

Open Access
1 Citation (Scopus)

A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma

Matsubara, T., Takada, K., Azuma, K., Takamori, S., Toyokawa, G., Haro, A., Osoegawa, A., Tagawa, T., Kawahara, A., Akiba, J., Okamoto, I., Nakanishi, Y., Oda, Y., Hoshino, T. & Maehara, Y., Jun 15 2019, In : Annals of Surgical Oncology. 26, 6, p. 1925-1933 9 p.

Research output: Contribution to journalArticle

5 Citations (Scopus)

Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma

Takada, K., Shimokawa, M., Tanaka, K., Kohashi, K., Haro, A., Osoegawa, A., Tagawa, T., Azuma, K., Okamoto, I., Oda, Y. & Mori, M., Jun 2019, In : PloS one. 14, 6, e0217991.

Research output: Contribution to journalArticle

Open Access

Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study)

Akamatsu, H., Koh, Y., Okamoto, I., Fujimoto, D., Bessho, A., Azuma, K., Morita, S., Yamamoto, N. & Nakagawa, K., May 2019, In : Lung Cancer. 131, p. 128-133 6 p.

Research output: Contribution to journalArticle

Open Access
3 Citations (Scopus)
16 Citations (Scopus)

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

Yoshioka, H., Shimokawa, M., Seto, T., Morita, S., Yatabe, Y., Okamoto, I., Tsurutani, J., Satouchi, M., Hirashima, T., Atagi, S., Shibata, K., Saito, H., Toyooka, S., Yamamoto, N., Nakagawa, K. & Mitsudomi, T., Dec 1 2019, In : Annals of Oncology. 30, 12, p. 1978-1984 7 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting

Park, K., Wan-Teck Lim, D., Okamoto, I. & Yang, J. C. H., Apr 1 2019, In : Therapeutic Advances in Medical Oncology. 11

Research output: Contribution to journalReview article

Open Access
2 Citations (Scopus)

Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA

Otsubo, K., Sakai, K., Takeshita, M., Harada, D., Azuma, K., Ota, K., Akamatsu, H., Goto, K., Horiike, A., Kurata, T., Nakagaki, N., Nosaki, K., Iwama, E., Nakanishi, Y., Nishio, K. & Okamoto, I., Jan 1 2019, In : Oncologist. 24, 8, p. 1022-1026 5 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Yonesaka, K., Iwama, E., Hayashi, H., Suzuki, S., Kato, R., Watanabe, S., Takahama, T., Tanizaki, J., Tanaka, K., Takeda, M., Sakai, K., Azuma, K., Chiba, Y., Atagi, S., Nishio, K., Okamoto, I. & Nakagawa, K., Dec 1 2019, In : Scientific reports. 9, 1, 19501.

Research output: Contribution to journalArticle

Open Access

Identification of genomic alterations acquired during treatment with EGFR-TKIs in non-small cell lung cancer

Kubo, N., Harada, T., Shiraishi, Y., Nosaki, K., Nakagaki, N., Takeshita, M., Ouchi, H., Iwama, E., Tanaka, K., Okamoto, I., Sasaki, H. & Nakanishi, Y., Feb 2019, In : Anticancer research. 39, 2, p. 671-677 7 p.

Research output: Contribution to journalArticle

Open Access

Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti–PD-1 therapy

Ikematsu, Y., Tanaka, K., Yanagihara, T., Liu, R., Inoue, H., Yoneshima, Y., Ota, K., Iwama, E., Takata, S., Hata, K., Takahata, Y., Wataya, H., Nakanishi, Y. & Okamoto, I., Dec 2019, In : Lung Cancer. 138, p. 58-64 7 p.

Research output: Contribution to journalArticle

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC

Sugawara, S., Nakagawa, K., Yamamoto, N., Nokihara, H., Ohe, Y., Nishio, M., Takahashi, T., Goto, K., Maemondo, M., Ichinose, Y., Seto, T., Sakai, H., Gemma, A., Imamura, F., Shingyoji, M., Saka, H., Inoue, A., Takeda, K., Okamoto, I., Kiura, K. & 2 others, Morita, S. & Tamura, T., May 15 2019, In : International Journal of Clinical Oncology. 24, 5, p. 485-493 9 p.

Research output: Contribution to journalArticle

Open Access

Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor

Hino, T., Kamitani, T., Sagiyama, K., Yamasaki, Y., Okamoto, I., Tagawa, T., Ijichi, K., Yamamoto, H., Yabuuchi, H. & Honda, H., Jan 1 2019, In : European Journal of Radiology Open. 6, p. 72-77 6 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Molecularly-targeted therapies for advanced non-small-cell lung cancer

Okamoto, I., Nov 25 2019, In : Japanese Journal of Lung Cancer. 59, p. 1115-1118 4 p.

Research output: Contribution to journalArticle

Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis

Hirashima, T., Satouchi, M., Hida, T., Nishio, M., Kato, T., Sakai, H., Imamura, F., Kiura, K., Okamoto, I., Kasahara, K., Uchida, H., Vowler, S. L. & Mitsudomi, T., Sep 1 2019, In : Cancer Science. 110, 9, p. 2884-2893 10 p.

Research output: Contribution to journalArticle

Open Access
2 Citations (Scopus)

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Ohe, Y., Imamura, F., Nogami, N., Okamoto, I., Kurata, T., Kato, T., Sugawara, S., Ramalingam, S. S., Uchida, H., Hodge, R., Vowler, S. L., Walding, A. & Nakagawa, K., Jan 1 2019, In : Japanese journal of clinical oncology. 49, 1, p. 29-36 8 p.

Research output: Contribution to journalArticle

7 Citations (Scopus)

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

Cho, B. C., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Sriuranpong, V., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cheng, Y., Cho, E. K., Voon, P. J., Lee, J. S., Mann, H., Saggese, M., Reungwetwattana, T., Ramalingam, S. S. & Ohe, Y., Jan 2019, In : Journal of Thoracic Oncology. 14, 1, p. 99-106 8 p.

Research output: Contribution to journalArticle

6 Citations (Scopus)

Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients

Nogami, N., Nishio, M., Okamoto, I., Enatsu, S., Suzukawa, K., Takai, H., Nakagawa, K. & Tamura, T., Jan 2019, In : Respiratory Investigation. 57, 1, p. 27-33 7 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer

Udagawa, H., Akamatsu, H., Tanaka, K., Takeda, M., Kanda, S., Kirita, K., Teraoka, S., Nakagawa, K., Fujiwara, Y., Yasuda, I., Okubo, S., Shintani, M., Kosloski, M. P., Scripture, C., Tamura, T. & Okamoto, I., Sep 2019, In : Lung Cancer. 135, p. 145-150 6 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients

Takamori, S., Takada, K., Azuma, K., Jogo, T., Shimokawa, M., Toyokawa, G., Hirai, F., Tagawa, T., Kawahara, A., Akiba, J., Okamoto, I., Nakanishi, Y., Oda, Y., Hoshino, T. & Maehara, Y., Jun 15 2019, In : Annals of Surgical Oncology. 26, 6, p. 1916-1924 9 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Nakagawa, K., Garon, E. B., Seto, T., Nishio, M., Ponce Aix, S., Paz-Ares, L., Chiu, C. H., Park, K., Novello, S., Nadal, E., Imamura, F., Yoh, K., Shih, J. Y., Au, K. H., Moro-Sibilot, D., Enatsu, S., Zimmermann, A., Frimodt-Moller, B., Visseren-Grul, C., Reck, M. & 96 others, Chu, Q., Cortot, A., Pujol, J. L., Fabre, E., Lamour, C., Bischoff, H., Kollmeier, J., Kimmich, M., Engel-Riedel, W., Hammerschmidt, S., Schütte, W., Syrigos, K., Ho, J. C. M., Au, K. H., Ardizzoni, A., Pasello, G., Gregorc, V., Del Conte, A., Galetta, D., Takahashi, T., Kumagai, T., Hotta, K., Goto, Y., Hosomi, Y., Sakai, H., Takiguchi, Y., Kim, Y. H., Kurata, T., Yamaguchi, H., Daga, H., Okamoto, I., Satouchi, M., Ikeda, S., Kasahara, K., Atagi, S., Azuma, K., Aoe, K., Horio, Y., Yamamoto, N., Tanaka, H., Watanabe, S., Nogami, N., Ozaki, T., Koyama, R., Hirashima, T., Kaneda, H., Tomii, K., Fujita, Y., Seike, M., Nishimura, N., Kato, T., Ichiki, M., Saka, H., Hirano, K., Nakahara, Y., Sugawara, S., Kim, S. W., Min, Y. J., Lee, H. W., Kang, J. H., An, H. J., Lee, K. H., Kim, J. S., Lee, G. W., Lee, S. Y., Alexandru, A., Udrea, A. A., Juan-Vidal, Ó., Nadal-Alforja, E., Gil-Bazo, I., Ponce-Aix, S., Rubio-Viqueira, B., Alonso Garcia, M., Felip Font, E., Fuentes Pradera, J., Coves Sarto, J., Lin, M. C., Su, W. C., Hsia, T. C., Chang, G. C., Wei, Y. F., Su, J., Cicin, I., Goksel, T., Harputluoglu, H., Ozyilkan, O., Henning, I., Popat, S., Hatcher, O., Mileham, K., Acoba, J., Garon, E., Jung, G., Raj, M., Martin, W. & Dakhil, S., Dec 2019, In : The Lancet Oncology. 20, 12, p. 1655-1669 15 p.

Research output: Contribution to journalArticle

7 Citations (Scopus)

Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)

Fukuda, M., Kitazaki, T., Ogawara, D., Ichiki, M., Mukae, H., Maruyama, R., Nakagaki, N., Shimada, M., Ikeda, T., Kishimoto, J., Harada, T., Seto, T., Ebi, N., Takayama, K., Okamoto, I., Ichinose, Y. & Sugio, K., Jun 2019, In : Lung Cancer. 132, p. 1-8 8 p.

Research output: Contribution to journalArticle

Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies

Yoneshima, Y., Tanaka, K., Shiraishi, Y., Hata, K., Watanabe, H., Harada, T., Otsubo, K., Iwama, E., Inoue, H., Masuda, S., Nakanishi, Y. & Okamoto, I., Apr 2019, In : Lung Cancer. 130, p. 5-9 5 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)

Nishio, M., Sugawara, S., Atagi, S., Akamatsu, H., Sakai, H., Okamoto, I., Takayama, K., Hayashi, H., Nakagawa, Y. & Kawakami, T., Nov 2019, In : Clinical Lung Cancer. 20, 6, p. 469-476.e1

Research output: Contribution to journalArticle

1 Citation (Scopus)

Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia

DLD/TO Assemblies of JRS, Nov 2019, In : Respiratory Investigation. 57, 6, p. 512-533 22 p.

Research output: Contribution to journalReview article

1 Citation (Scopus)

Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401

Iwama, E., Goto, Y., Murakami, H., Tsumura, S., Sakashita, H., Mori, Y., Nakagaki, N., Fujita, Y., Seike, M., Bessho, A., Ono, M., Nishitsuji, M., Akamatsu, H., Morinaga, R., Akagi, T., Shimose, T., Tokunaga, S., Yamamoto, N., Nakanishi, Y., Sugio, K. & 1 others, Okamoto, I., Jan 1 2019, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Open Access

Tissue and plasma EGFR mutation analysis in the FLAURA trial: Osimertinib versus Comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non–small cell lung cancer

Gray, J. E., Okamoto, I., Sriuranpong, V., Vansteenkiste, J., Imamura, F., Lee, J. S., Pang, Y. K., Cobo, M., Kasahara, K., Cheng, Y., Nogami, N., Cho, E. K., Su, W. C., Zhang, G., Huang, X., Li-Sucholeiki, X., Lentrichia, B., Dearden, S., Jenkins, S., Saggese, M. & 2 others, Rukazenkov, Y. & Ramalingam, S. S., Nov 15 2019, In : Clinical Cancer Research. 25, 22, p. 6644-6652 9 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer

Tsuchiya-Kawano, Y., Sasaki, T., Yamaguchi, H., Hirano, K., Horiike, A., Satouchi, M., Hosokawa, S., Morinaga, R., Komiya, K., Inoue, K., Fujita, Y., Toyozawa, R., Kimura, T., Takahashi, K., Nishikawa, K., Kishimoto, J., Nakanishi, Y. & Okamoto, I., Jan 1 2019, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Open Access
2018

Anticancer drug treatment for advanced lung cancer with interstitial lung disease

Otsubo, K., Okamoto, I., Hamada, N. & Nakanishi, Y., Jul 2018, In : Respiratory Investigation. 56, 4, p. 307-311 5 p.

Research output: Contribution to journalReview article

4 Citations (Scopus)

Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients

Anai, S., Iwama, E., Yoneshima, Y., Otsubo, K., Tanaka, K., Nakanishi, Y. & Okamoto, I., Dec 2018, In : Lung Cancer. 126, p. 156-161 6 p.

Research output: Contribution to journalArticle

Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers

Akamine, T., Takada, K., Toyokawa, G., Kinoshita, F., Matsubara, T., Kozuma, Y., Haratake, N., Takamori, S., Hirai, F., Tagawa, T., Okamoto, T., Yoneshima, Y., Okamoto, I., Shimokawa, M., Oda, Y., Nakanishi, Y. & Maehara, Y., Mar 2018, In : Surgical Oncology. 27, 1, p. 88-94 7 p.

Research output: Contribution to journalArticle

12 Citations (Scopus)

Clinical significance of PD-L1 expression in brain metastases from non-small cell lung cancer

Takamori, S., Toyokawa, G., Okamoto, I., Takada, K., Kinoshita, F., Kozuma, Y., Matsubara, T., Haratake, N., Akamine, T., Mukae, N., Hirai, F., Tagawa, T., Oda, Y., Iwaki, T., Iihara, K., Nakanishi, Y. & Maehara, Y., Jan 2018, In : Anticancer research. 38, 1, p. 553-557 5 p.

Research output: Contribution to journalArticle

8 Citations (Scopus)

CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer

Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., Okamoto, I., Leighl, N., Hodge, R., McKeown, A., Brown, A. P., Rukazenkov, Y., Ramalingam, S. S. & Vansteenkiste, J., Nov 20 2018, In : Journal of Clinical Oncology. 36, 33, p. 3290-3297 8 p.

Research output: Contribution to journalArticle

71 Citations (Scopus)

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer

Iwama, E., Nakanishi, Y. & Okamoto, I., Mar 4 2018, In : Expert Review of Anticancer Therapy. 18, 3, p. 267-276 10 p.

Research output: Contribution to journalReview article

5 Citations (Scopus)

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade

Tanaka, K., Yanagihara, T., Ikematsu, Y., Inoue, H., Ota, K., Kashiwagi, E., Suzuki, K., Hamada, N., Takeuchi, A., Tatsugami, K., Eto, M., Ijichi, K., Oda, Y., Otsubo, K., Yoneshima, Y., Iwama, E., Nakanishi, Y. & Okamoto, I., Jul 17 2018, In : Oncotarget. 9, 55, p. 30587-30593 7 p.

Research output: Contribution to journalArticle

6 Citations (Scopus)

Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer

Otsubo, K., Seki, N., Nakanishi, Y. & Okamoto, I., Mar 1 2018, In : Annals of Oncology. 29, 3, p. 780-781 2 p.

Research output: Contribution to journalLetter

1 Citation (Scopus)

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis

Ide, M., Tanaka, K., Sunami, S., Asoh, T., Maeyama, T., Tsuruta, N., Nakanishi, Y. & Okamoto, I., Nov 2018, In : Thoracic Cancer. 9, 11, p. 1519-1521 3 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results

Kato, T., Seto, T., Nishio, M., Goto, K., Yamamoto, N., Okamoto, I., Tao, L., Yu, W., Khaznadar, T., Tajima, K., Shibata, M., Seki, A. & Yamamoto, N., Feb 1 2018, In : Drug Safety. 41, 2, p. 229-237 9 p.

Research output: Contribution to journalArticle

12 Citations (Scopus)

Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing

Iwama, E., Sakai, K., Azuma, K., Harada, D., Nosaki, K., Hotta, K., Nishio, M., Kurata, T., Fukuhara, T., Akamatsu, H., Goto, K., Shimose, T., Kishimoto, J., Nakanishi, Y., Nishio, K. & Okamoto, I., Dec 2018, In : Cancer Science. 109, 12, p. 3921-3933 13 p.

Research output: Contribution to journalArticle

9 Citations (Scopus)

Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer

Kimura, S., Harada, T., Ijichi, K., Tanaka, K., Liu, R., Shibahara, D., Kawano, Y., Otsubo, K., Yoneshima, Y., Iwama, E., Nakanishi, Y. & Okamoto, I., Jun 2018, In : Lung Cancer. 120, p. 98-107 10 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionization mass spectrometry imaging: a pilot study

Ryu, S., Hayashi, M., Aikawa, H., Okamoto, I., Fujiwara, Y. & Hamada, A., Jan 2018, In : British Journal of Pharmacology. 175, 1, p. 29-37 9 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)